Search results - 3 results
A Comparative Immunogenicity and Safety Trial of Two Different Schedules of Single-visit Intradermal Rabies Post-exposure Vaccination Following a Single-visit Pre-exposure Vaccination.
for immunogenicity was the percentage of subjects with an adequate antibody level (>0.5 IU /mL) seven days after the booster doses. The safety endpoint was the proportion of participants developing ...
Inhibition of MALT1 decreases neuroinflammation and pathogenicity of virulent rabies virus in mice.
disease development after infection with the virulent rabies virus strain CVS-11. Morbidity and mortality were significantly delayed in compared to mice, which was associated with a lower viral load, ...
Pre-exposure intradermal rabies vaccination: a non-inferiority trial in healthy adults on shortening the vaccination schedule from 28 to 7 days.
with an adequate antibody level >0.5 IU /mL seven days after the booster injection. The safety endpoint was the proportion of participants developing adverse reactions following the primary ...